Inhaled nitric oxide (iNO) and nebulized epoprostenol selectively vasodilate ventilated pulmonary capillary beds, improving V/Q matching and lowering pulmonary arterial pressure without systemic hypotension.

Key Physiological Equations & Formulas

  • Nitric Oxide Mechanism: $$\text{L-Arginine} \rightarrow \text{NO} \rightarrow \text{sGC} \rightarrow \text{cGMP} \rightarrow \text{Vasodilation}$$ Inactivated immediately upon contact with hemoglobin to form methemoglobin.

Practical Clinical Pearls & Bedside Rules

  • Standard Starting Dose: Start iNO at 20 ppm. Higher doses (>20 ppm) rarely improve oxygenation but significantly increase methemoglobin and nitrogen dioxide ($NO_2$) toxicity.
  • Weaning Protocol: Wean gradually: 20 -> 10 -> 5 -> 2 -> 1 ppm before discontinuation to prevent life-threatening rebound pulmonary hypertension.

Initial Settings & Clinical Titration Protocol

ParameterRecommended Initial SettingTitration Goal / Safety Threshold
Initial Dose20 ppmAssess response within 30-60 minutes (rise in PaO2 > 20 mmHg or OI drop > 20%).
Methemoglobin SurveillanceMonitor co-oximetry daily (keep MetHb < 2.5-3.0%)If MetHb > 5%, reduce iNO dose.

Bedside Troubleshooting & Red Flags

Warning

Rebound Pulmonary Hypertension: Abrupt discontinuation of iNO can cause fatal acute right ventricular failure. Never stop iNO abruptly.

Key Takeaways & Summary

  1. Always evaluate patient synchrony and physiological response before changing ventilator parameters.
  2. Maintain lung-protective strategies to minimize driving pressure ($\Delta P$) and mechanical power.
  3. Continuously reassess liberation and extubation readiness on daily morning rounds.